![]() |
Dr. Reddy's Laboratories posts net loss at Rs569.7cr |
Q3FY20 financials include an impairment charge of Rs1,320cr on some of the company's products forming part of Global Generics and Proprietary Products segments, the pharma company said in the filing.
- Revenues from Emerging Markets came it at Rs920cr, with a 19% yoy growth and 11% as sequential growth.
- Revenues from Russia at Rs490cr, 20% growth on a yoy basis driven by an increase in volumes coupled with better realizations in some of the key molecules.
- Revenues from other CIS countries and Romania market at Rs180cr, 26% yoy growth largely driven by new products and volume traction.
- Revenues from India at Rs760cr, with a yoy growth of 13%, led by new products, improved realizations in base business and volume traction. Sequential growth is 2% due to improved realizations and launch of new products.
- Revenues from Europe at Rs310cr, with a yoy growth of 52%, primarily on account of new products and volume traction in base business partly offset by lower realizations as few key molecules entered tenders. Sequential growth is 12% due to improvement in the sales of the base business.
- Revenues from Rest of World (RoW) territories at Rs250cr, up 12% yoy, primarily driven by new products coupled with volume traction partly offset by price erosions in some of the key molecules.
Stock view:
Dr Reddys Laboratories Ltd is currently trading at Rs3,114.55, up by Rs86.5 or 2.86% from its previous closing of Rs3,028.05 on the BSE.
The scrip opened at Rs3,037.45 and has touched a high and low of Rs3,115.85 and Rs3,001.60 respectively.
0 comments:
Post a Comment
Please add comment